Compare Abeona Therapeutics Inc (ABEO) vs SOLAI Limited (SLAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs SOLAI Limited — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while SOLAI Limited trades at $3.04 (market cap $14.40M). The key difference: Abeona Therapeutics Inc is far larger — about 25.9× SOLAI Limited's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| ABEO | SLAI | |
|---|---|---|
Market Cap | $373.32M | $14.40M |
Sector | Health | Technology |
52-Week High | $7.23 | $43.75 |
52-Week Low | $4.17 | $2.74 |
Enterprise Value | $228.22M | $14.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SLAI trades at $3.27, up 5.48% today, but faces significant financial challenges with negative profitability metrics including a -134.63% net income margin and -$33.88M net loss for 2025. The company recently completed a 7:1 reverse stock split and acquired a 51% stake in NEURALAND while receiving NYSE listing standard notices. Technical indicators show a bearish trend with support at $3 and resistance at $4.
Despite recent acquisitions and product launches, SLAI's persistent losses and negative cash flow present substantial investment risks. The single analyst covering the stock maintains a Hold rating, reflecting cautious sentiment amid ongoing financial restructuring and competitive pressures in the AI infrastructure market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
